ArticleCancer biomarkers : section A of Disease markers2019
Downregulated circular RNA itchy E3 ubiquitin protein ligase correlates with advanced pathologic T stage, high lymph node metastasis risk and poor survivals in prostate cancer patients.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Prognostic and diagnostic value of circRNA expression in prostate cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review.Frontiers in cell and developmental biology · 2021Pooled it
- Prognostic and Clinicopathological Significance of Circular RNA circ-ITCH Expression in Cancer Patients: A Meta-analysis.BioMed research international · 2021Pooled it
- Exploring the role of circular RNAs in endometrial cancer progression and chemoresistance: Implications for targeted therapies.European journal of medical research · 2025Review
- Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025Review
- Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance.Cancer metastasis reviews · 2024Review
- Role of Circular RNAs in Prostate Cancer.Current medicinal chemistry · 2024Review
- The function and mechanisms of action of circular RNAs in Urologic Cancer.Molecular cancer · 2023Review
- Circular RNA ITCH: An Emerging Multifunctional Regulator.Biomolecules · 2022Review
- CircRNA ITCH: Insight Into Its Role and Clinical Application Prospect in Tumor and Non-Tumor Diseases.Frontiers in genetics · 2022Review
- Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance.Molecular therapy. Nucleic acids · 2021Review
- Review
- CircITCH: A Circular RNA With Eminent Roles in the Carcinogenesis.Frontiers in oncology · 2021Review
- The Role and Clinical Potentials of Circular RNAs in Prostate Cancer.Frontiers in oncology · 2021Review
- Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering.International journal of biological sciences · 2021Review
- Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors.International journal of molecular sciences · 2020Article
- Circ-MTO1 correlates with favorable prognosis and inhibits cell proliferation, invasion as well as miR-17-5p expression in prostate cancer.Journal of clinical laboratory analysis · 2020Article
- Circular RNA_PDHX Promotes the Proliferation and Invasion of Prostate Cancer by Sponging MiR-378a-3p.Frontiers in cell and developmental biology · 2020Article
- Hsa_circ_0088233 Alleviates Proliferation, Migration, and Invasion of Prostate Cancer by Targeting hsa-miR-185-3p.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the correlation of circular RNA itchy E3 ubiquitin protein ligase (circ-ITCH) with pathological features as well as its predictive value on prognosis in prostate cancer patients.
methodsThree hundred and twenty-four patients with prostate cancer underwent radical prostatectomy were consecutively included in this retrospective study, and patients' specimens of tumor as well as paired adjacent tissues were collected for detection of circ-ITCH expression. Patients' baseline characteristics and survival data were obtained from follow-up records, and correlation of circ-ITCH with patients' pathological features and survival was determined.
resultsCirc-ITCH expression was decreased in tumor tissue compared with paired adjacent tissues (P< 0.001), and it presented with good value in distinguishing tumor tissues from paired adjacent tissues with area under curve (AUC) of 0.812 (95%CI: 0.780-0.845). Circ-ITCH low expression was associated with advanced pathologic T stage (P= 0.002) and high risk of lymph node metastasis (P= 0.047) in prostate cancer patients. As for prognosis, patients with circ-ITCH high expression had longer disease-free survival (DFS) (P< 0.001) and overall survival (OS) (P< 0.001). Additionally, circ-ITCH (high vs. low) independently predicted better survival, while Gleason score (> 7 vs. ⩽ 7) and surgical margin status (positive vs. negative) independently predicted worse survival in prostate patients underwent radical prostatectomy.
conclusionsCirc-ITCH is downregulated in prostate cancer tissues, and its low expression correlates with advanced pathologic T stage, high lymph mode metastasis risk and poor survival in prostate cancer patients underwent radical prostatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.